Simone van de Sande-Lee

Simone van de Sande-Lee

Auto-generated profile, based on publicly available information

Simone van de Sande-Lee

Universidade Federal de Santa Catarina

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2024 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
TTTalita Trevisan
Talita Trevisan
EPEric Pasqualotto
Eric Pasqualotto
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
BMBeatriz Friedrichsen Marques
Beatriz Friedrichsen Marques
SSSimone van de Sande-Lee
Simone van de Sande-Lee
Introduction: Continuous glucose monitoring (CGM) has shown favorable outcomes in patients with type 2 diabetes (T2D) who are on insulin therapy. However, the efficacy of CGM in managing glucose levels in noninsulin-treated people with T2D remains controversial. Methods: PubMed, Cochrane, and Embase were searched for randomized controlled trials (RCTs) comparing CGM to self-monitoring of blood glucose (SMBG) in people with T2D not using insulin. We computed weighted mean differences (WMDs) and standard mean differences (SMD) for continuous outcomes, with 95% confidence intervals (CIs). Heterogeneity was assessed using I 2 statistics. Statistical analyses were performed using R version 4.2.3. Results: We included six RCTs comprising 407 noninsulin-treated people with T2D of whom 228 were randomized to CGM. Diabetes duration ranged from 5.4 to 13.9 years. The mean age was 57.9 years and the mean body mass index was 30.8 kg/m 2 . Four trials used real-time CGM (rt-CGM) and two intermittent scanning CGM (is-CGM). Compared with SMBG, CGM significantly reduced the glycated hemoglobin level (WMD −0.31%; 95% CI −0.42 to −0.21; I 2 = 0%), glucose level (WMD −11.16 mg/dL; 95% CI −19.94 to −2.39; I 2 = 0%), time in hypoglycemia level 2 (WMD −0.28%; 95% CI −0.52 to −0.03; I 2 = 91%), glucose time >180 mg/dL (WMD −7.75%; 95% CI −12.04 to −3.45; I 2 = 0%), and the standard deviation of glucose variation (WMD −4.00 mg/dL; 95% CI −6.86 to −1.14; I 2 = 0%). CGM also increased time in range (WMD 8.63%; 95% CI 4.54–12.71; I 2 = 0%) and treatment satisfaction (SMD 0.79; 95% CI 0.54–1.05; I 2 = 0%). Conclusion: In this meta-analysis, rt-CGM and is-CGM were associated with improvement in glycemic control in people with T2D not using insulin when compared to SMBG.

7 May 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
FRFernanda Augustini Rigon
Fernanda Augustini Rigon
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
AHAlexandre Hohl
Alexandre Hohl
SSSimone van de Sande-Lee
Simone van de Sande-Lee

3 April 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
EPEric Pasqualotto
Eric Pasqualotto
JWJanine Midori Figueiredo Watanabe
Janine Midori Figueiredo Watanabe
DGDouglas Mesadri Gewehr
Douglas Mesadri Gewehr
RMRaphaela da Silva Maintinguer
Raphaela da Silva Maintinguer
SSSimone van de Sande‐Lee
Simone van de Sande‐Lee
CPCarlos Eduardo Andrade Pinheiro
Carlos Eduardo Andrade Pinheiro

13 September 2024 in Metabolism Open
Verified
Journal Article
Open access
EPEric Pasqualotto
Eric Pasqualotto
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
AHAlexandre Hohl
Alexandre Hohl
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
SSSimone van de Sande-Lee
Simone van de Sande-Lee
To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for placebo-controlled, randomized clinical trials (RCTs) published up until February 23, 2024. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) for binary endpoints were computed, with 95 % confidence intervals (CIs). A total of three studies were included, comprising 640 patients, of whom 510 were prescribed retatrutide. Compared with placebo, retatrutide significantly reduced body weight (WMD -10.66 kg; 95 % CI -17.63, −3.69), body mass index (WMD -4.53 kg/m2; 95 % CI -7.51, −1.55), and waist circumference (WMD -6.61 cm; 95 % CI -13.17, −0.05). In addition, retatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥5 % (RR 2.92; 95 % CI 2.17–3.93), ≥10 % (RR 9.32; 95 % CI 4.56–19.06), ≥15 % (RR 18.40; 95 % CI 6.00–56.42), and ≥20 % (RR 16.61; 95 % CI 4.17–66.12). In this meta-analysis, the use of once-weekly subcutaneous retatrutide was associated with a significant reduction in body weight and improvement of metabolic markers in patients with overweight, obesity and/or T2D, compared with placebo, with an increase in non-severe gastrointestinal and hypersensitivity adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term.

11 September 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
CLCarine Lütkemeyer
Carine Lütkemeyer
EPEric Pasqualotto
Eric Pasqualotto
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
IPIlmar Petris
Ilmar Petris
SSSimone van de Sande-Lee
Simone van de Sande-Lee
The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) or risk differences for binary endpoints were computed, with 95% confidence intervals (CIs). Heterogeneity and risk of [...] ABSTRACT The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched until February 2024 for randomized controlled trials (RCTs) comparing orforglipron versus placebo or other anti-obesity medications in adult patients. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) or risk differences for binary endpoints were computed, with 95% confidence intervals (CIs). Heterogeneity and risk of

1 January 2025 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
AHAlexandre Hohl
Alexandre Hohl
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
EPEric Pasqualotto
Eric Pasqualotto
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
SSSimone van de Sande-Lee
Simone van de Sande-Lee
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
Objective: This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. Materials and methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Weighted mean differences [...] Abstract Objective: This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. Materials and methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Weighted mean differences